Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
NEW YORK, Feb. 01, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Cnova N.V. (“Cnova”) (NASDAQ:CNV) pursuant and/or traceable to the Initial Public Offering on or about November 19, 2014, and/or between November 19, 2014 and December 18, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Cnova N.V. securities between November 19, 2014 and December 18, 2015, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/cnovacnv.
The Complaint alleges that during the Class Period, defendants failed to disclose that Cnova issued misleading financial statements by failing to disclose that the Company lacked adequate internal financial controls and that it had overstated net sales, failed to properly write-off the value of returned items, misstated accounts receivable for damaged/returned items, and overstated EBIT.
If you suffered a loss in Cnova you have until March 21, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/cnovacnv.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
